INTRODUCTION
Myotonic dystrophy (DM, Steinert's disease) is a dominant, inheritable multisystem disease. Symptoms include skeletal muscle weakness, wasting and myotonia, cardiac conduction defects, gastrointestinal problems, cognitive and behavioural alterations, hypersomnia, cataract and insulin resistance (1, 2) . DM is one of the most frequent genetic diseases and also one of the most variable disorders. Symptoms and severity vary greatly among family members and between generations. Patients may remain undiagnosed or be misdiagnosed for years, if not recognized as member of a DM family (1) . No cure to stop or halt disease progression is available yet and clinical management is limited to symptomatic treatment. A series of recent publications on novel options for molecular therapy suggest that this situation may be changing. Here, we will discuss new drug-based approaches, which aim to ameliorate the effects of RNA toxicity.
GENETICS AND MOLECULAR PATHOGENESIS OF DM
Two forms of DM are known, each with its own genetic mutation. DM type 1 is caused by an unstable (CTG †CAG)n repeat of 80 to several thousand triplets, located in the 3 ′ untranslated region of the DMPK gene (3, 4) . DM type 2 is caused by an expanding (CCTG †CAGG)n repeat of 75-11 000 units in the first intron of the ZNF9 gene (5) . DM2 shows a generally milder pattern than DM1 and lacks a congenital form [for comparison of clinical manifestations, see (2, 6) ].
Above a critical length, (CTG †CAG)n and (CCTG †CAGG)n repeats tend to expand in somatic cells during a patient's life and from one generation to the next (7) (8) (9) . For DM1, it has been demonstrated most clearly that growth of the (CTG †CAG)n repeat is related to an increased disease severity and earlier age of onset (1, 2) . The length of the repeat alone cannot explain disease variability, however. Recent work has revealed that the presence of CCG †CGG sequence interruptions at the 3 ′ end of a (CTG †CAG)n tract is a feature that probably contributes to disease variability (10, 11) . The impact of this fascinating finding for our understanding of DM's molecular pathogenesis is still unclear.
To be able to develop therapeutic avenues, a unifying hypothesis is needed to explain how two different mutations in genes with entirely different structure and function can cause comparable phenotypes. Currently, the most broadly accepted theory implicates a shared toxic RNA gain-of-function for non-coding expanded (CUG)n and (CCUG)n transcripts, also called RNA dominance (reviewed in 12,13, Fig. 1 ). Abnormal, long transcripts from mutant DMPK or ZNF9 alleles bind or sequester proteins that function in transcription, splicing or RNA export and can be retained in cell nuclei in small ribonuclear complexes or microscopically visible inclusions (5, 14) . Members of the muscleblind (MBNL) family are the best studied proteins involved (15, 16) . CUG-binding protein 1 (CUGBP1), whose expression is increased in DM1 patients, also plays an important Figure 1 . RNA dominance and molecular therapeutic targets in myotonic dystrophy. Sequence of events according to the RNA toxicity model for the molecular pathogenesis of DM (left part). Two independent, unstable microsatellite repeats located in DMPK and ZNF9 genes give rise to expression of toxic, expanded RNAs with detrimental effects to the cell (black arrows). (C/CUG)n transcripts form thermodynamically stable hairpin structures that attract and sequester RNA-binding proteins, in particular members of the MBNL family and CUGBP1. Imbalance of these, and potentially other proteins results in disturbance of particular cellular mechanisms and pathways, of which aberrant splicing of a DM-typical subset of transcripts is the best studied example. Spliceopathy results in abnormal protein expression of, for example, chloride channel 1 (ClC-1) and insulin receptor (IR). Aberrant protein expression of DM locus genes and certain transcription factors may be caused by other, still not fully resolved mechanisms and may have an additive role in DM's molecular pathogenesis. Potential therapeutic targets and strategies at the level of DNA, RNA and protein are indicated in boxes on the right. See text for further details, which is focussed on molecular therapy at the RNA level.
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role (17) (18) (19) (20) . Next to trans-effects of (C/CUG)n RNA expression in the nuclear compartment, detrimental consequences for translation, proliferation and cell stress in the cytoplasm have recently gained attention (21) (22) (23) (24) (25) (26) . MBNL1 and CUGBP1 are antagonistic RNA-binding proteins and their abnormal expression in DM leads to transcription abnormalities (27, 28) and misregulation of splicing of a distinct subset of pre-mRNAs (29) (30) (31) . The relevance of a protein imbalance of MBNL1 and CUGBP1 was demonstrated in cell and animal models which display selected features of DM (28,32 -37) . Caution should be taken against overinterpretation of these findings, however, as none of these models replicates all features observed in DM patients and other mechanistic contributions to certain aspects of DM pathology may be involved (2, (38) (39) (40) (41) .
Molecular therapeutic strategies for DM1 can be directed specifically at the level of DNA, RNA or protein (Fig. 1) . Therapy aimed at stopping the root cause of the disease, the process of repeat expansion itself (7-9), is not currently possible, although novel technologies (42) (43) (44) may prove beneficial in the future and small molecules reducing somatic expansion have been identified (reviewed in 45). Therapy directed against molecular effects of repeat expansion-the other end of the pathogenic cascade-aimed at correction of aberrant splicing (46) , or replacement of MBNL1 (47) or restoration of normal CUGBP1 protein expression (48) may hold more promise (Fig. 1) . Here, we will focus on strategies designed for reduction of RNAmediated toxicity by selective targeting of expanded RNA.
TOXIC REPEAT RNA EFFECTS ARE REVERSIBLE
Expression of an expanded (CUG)n segment-in the context of DMPK gene sequences or as part of an unrelated gene-recapitulated specific DM characteristics in a series of in vitro and in vivo models (32,49 -53) . Development of an inducible skeletal muscle and heart model for DM1 revealed that reversal of disease features could be achieved by down-regulation of aberrant RNA expression only (54, 55) . Although this latter study was the first to provide an important proof of principle for in vivo reversal, more work needs to be done, because it is still enigmatic why this mouse model displays DM1 features based on the robust inducible expression of a DMPK 3 ′ UTRcontaining transgene with only five CTG triplets (54) . The field is therefore eagerly awaiting reversal studies with mouse models with longer CTG repeats. Importantly, in a separate study, correction of phenotypic effects was observed after complementation of Mbnl1 protein in an expanded (CUG)n RNA mouse model (47) . Taken together, these observations provide the foundation for two possible therapeutic strategies for DM, aimed at (i) degradation of the expanded (C/CUG)n RNA and (ii) prevention of aberrant protein binding (Fig. 1 ).
STRATEGIES TO DEGRADE (C/CUG)N EXPANDED TRANSCRIPTS
Existing approaches to eliminate toxic DM transcripts are based on nucleic acid(-like) compounds that hybridize to target sequences in DMPK RNA [no reports on silencing of ZNF9 (CCUG)n RNA have been published up to now]. Two outcome options should be distinguished: (i) removal of all DMPK transcripts, irrespective of repeat length, or (ii) selective elimination of expanded DMPK RNAs only. Regarding the latter possibility, apart from the length of the (CUG)n segment, there is no general polymorphism known that allows discrimination between mRNAs from normal-sized DMPK alleles and expanded transcripts from mutated alleles in each DM patient. Non-selective transcript removal, option (i), may have adverse consequences because this will lead to loss of DMPK protein. We can only speculate about the possible side effects of DMPK protein loss. KO mice lacking DMPK protein show a relatively mild phenotype (56, 57) and the few patients with homozygous DMPK expansions do not display abnormally severe symptoms (58) . A remaining low level of DMPK protein may therefore suffice to safeguard the functional integrity of cells in which it is expressed. Another unknown issue is what minimum efficacy of knockdown is needed for a beneficial effect. Based on data that will be discussed in more detail below, one may expect that partial silencing of toxic (CUG)n RNA may already be of clinical relevance to patients.
Ribozymes and conventional antisense strategies
The first paper on direct targeting of DMPK transcripts described a Tetrahymena trans-splicing group I intron ribozyme which was able to swap part of the 3 ′ end of a DMPK transcript for a similar fragment contained within the ribozyme, thereby reducing the number of CUG triplets from 12 to 5 (59) . A comparable approach employed the so-called artificial trans-splicing molecules (60), which induced a transsplicing event involving 3 ′ exon replacement during DMPK pre-mRNA splicing (61) . RNA repair of pathogenic (CUG)n segments was not tested in either study, and efficiency and specificity require further optimization. Also the fate of the excised segment should be studied, as any toxic effect out of the context of the DMPK transcript should be avoided [compare the stable (CCUG)n intron in DM2 (62)].
A hammerhead-type of ribozyme to induce endonucleolytic cleavage of DMPK transcripts was designed by Puymirat et al. (63) . This group achieved a 60% reduction of expanded transcripts, a drop in the number of nuclear RNA foci and partial restoration of insulin receptor missplicing. Cytoplasmic DMPK transcripts were also 50% reduced, despite measures to confine ribozymes to the cell nucleus. The poor specificity and relatively low efficiency remain therefore a concern for in vivo application of this ribozyme.
Conventional antisense strategies to evoke degradation of expanded DMPK transcripts have also been tested. A 149 bp antisense RNA complementary to part of the 3 ′ UTR of DMPK mRNA including a (CUG)13 repeat was expressed in patient myoblasts and resulted in correction of CUGBP1 expression and restoration of myoblast functions (64) . Expanded transcripts were reduced by 80% but also normal DMPK transcripts were 50% lower. A second antisense approach (63) tested DNA antisense oligonucleotides (AONs) complementary to sequences in DMPK's 3 ′ UTR in patient cell extracts for their ability to recruit RNase H, which degrades the RNA component of an RNA -DNA hybrid (65) . Only some oligos were able to induce degradation, confirming that accessi-
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bility of the target sequence, which depends on local RNA structure and presence of RNA-binding proteins, is a crucial factor for success in antisense approaches (66) .
RNA interference
(CUG)n repeats form stable hairpin structures (67) (68) (69) in which the stem may adopt a conformation very similar to A-form RNA, despite the U †U mismatches (70) . Any such RNA structure may be a target of the RNA interference (RNAi) pathway (70, 71) . Krol et al. provided evidence that expanded (CUG)n RNAsand other tandem (CNG)n sequences-are indeed recognized by Dicer (72), which cuts double-stranded RNA precursors into 21 nt duplexes (73) . Treatment of patient fibroblasts with a synthetic 5
′ monophosphorylated (AGC)7 RNA oligo resulted in a selective reduction of mutant DMPK transcripts (72) . It is unclear whether this RNA repeat oligo activated the RNAi pathway by forming imperfect (AGC)7 hybrids or by hybridizing with (CUG)n sequences in mutant DMPK transcripts, or whether an alternative degradation mechanism was operating.
In a second RNAi study, both cytoplasmic (normal) and nuclear-retained (expanded) DMPK transcripts were reduced after treatment of DM1 cells with lentiviral vectors that delivered short hairpin RNA targeting sequences in the 5 ′ end of the RNA (74) . This underscores the idea that RNAi is active in the nucleus as well as the cytoplasm (75) . Synthetic siRNAs targeting the same 5
′ DMPK sequences were also tested, but efficacy and location of activity strongly depended on the method of delivery (74) . SiRNA approaches targeting (CUG)n repeats specifically have not been published to date. Two studies on other triplet repeat diseases suggest that expanded (CAG)n sequences are not preferential targets for RNAi and that associated SNPs should be included for allele-specific silencing of mutant transcripts (76, 77) .
Antisense 2 ′ -O-methyl phosphorothioate (CAG)7 oligo PS58
Our own laboratory designed AONs (78) with the aim to degrade expanded DMPK transcripts directly by recruiting RNase H (65), or induce exon skipping (79, 80) or abortive splicing followed by conventional RNA breakdown (81, 82) . Prior background knowledge about the mode of action, stability against nucleolytic degradation, hybridization strength or cell penetration characteristics determined our AON design (65) . The most effective oligo identified, PS58, was directed against the (CUG)n repeat itself (78). This 2 ′ -O-methyl phosphorothioatemodified (CAG)7 AON reduced the expanded DMPK transcript levels by 70 -90% in a DM1 mouse cell model and in patient myoblast cultures. Normal-sized DMPK transcripts bearing a (CUG)5 repeat and other transcripts that contain a short (CUG)n repeat were left virtually intact. Findings were corroborated in transgenic mice from the DM300 [which express human DMPK (CUG)500 transcripts (83) ] and HSA LR lines [which express high amounts of an expanded (CUG)250 repeat in the context of a skeletal a-actin gene (32) ]. Local administration of PS58 in skeletal muscle resulted in 50% reduction of (CUG)n RNA in both models. As a result, two hallmarks of DM1-related RNA toxicity in HSA LR skeletal muscle were alleviated: nuclear (CUG)n RNA foci were reduced and DM1-typical splicing abnormalities were improved, albeit not to such an extent that muscle myotonia was reduced (78) .
Thus far, we have no insight in the molecular pathway behind PS58-induced degradation. We could not find evidence for induction of alternative splicing, despite PS58's chemical characteristics of a steric blocking-type oligo. PS58 activity may have mechanistic features in common with that of a (AGC)8A morpholino developed by the Thornton lab (84, see below for additional details) and also with action of a G(CTG)6 locked nucleic acid-containing oligo, which reduced expanded (CAG)n RNA in a Huntington's disease (HD) study (85) . In all three reports, triplet repeat AONs reduce expanded transcripts by unidentified mechanisms, unlikely to involve RNase H.
Other potential strategies to eliminate toxic (C/CUG)n transcripts
What other relevant technologies could be implemented to eliminate toxic (C/CUG)n RNA? First, DNAzymes, small ( 30 nt) DNA sequences which bind a particular RNA sequence and carry an intrinsic endoribonuclease activity (86) , have been employed to degrade expanded (CAG)n transcripts in HD (87) . Among a number of target sequences tested, the (CAG)n segment itself appeared a poor substrate, but this might work out differently for (C/CUG)n repeats.
A second example is splice switching, induced by steric blocking AONs. This has been successfully applied to many disease-relevant genes (88), like those involved in Duchenne muscular dystrophy, spinal muscular atrophy and also to chloride channel 1 (ClC-1) in DM1 (46) . Our small scale attempt was unsuccessful (78) , but DMPK pre-mRNA should be considered a good target for splice switching oligos because the (CUG)n repeat segment is located in the final 3 ′ exon, which takes part in a number of alternative splicing events (79,80, own unpublished data). For splice switching to be useful for DM1, it will probably be important that the spliced-out segment carrying the repeat expansion be degraded.
Thirdly, inhibition of transcription would be a means of preventing expanded RNAs from actually being formed. Peptide nucleic acids (PNAs) are oligonucleotides with the ability to invade double-stranded DNA and inhibit transcription (89) . Transcription-blocking PNAs have been identified for (CAG †CTG)n and (GAA †TTC)n repeat-containing genes (90,91), but we are not aware of the use of these tools in DM studies. PNAs should be appropriately designed or otherwise they may have deleterious effects throughout the genome.
A fourth possible approach would be the use of antigene RNAs (agRNAs), short double-stranded RNA molecules that target gene promoters rather than RNAs. The working mechanism of agRNAs is still somewhat obscure, but similar to PNAs, they are able to inhibit (92) [or activate! (93)] gene expression.
INHIBITION OF PROTEIN BINDING TO THE (C/CUG)N REPEAT HAIRPIN
A second approach to reduce RNA dominance involves prevention of abnormal protein factor binding to thermodynamically stable (C/CUG)n hairpin structures. Preclusion of binding might restore the level of the free protein factor, such that it
would become available for normal biological function, and re-establish normal mRNA nucleocytoplasmic transport.
Morpholino CAG25
In an exemplary study, Wheeler et al. (84) described the use of a 25 nt (AGC)8A morpholino-type AON (named CAG25) complementary to the (CUG)n repeat. Morpholinos are a type of AONs acting via an occupancy-only mechanism by hybridizing to a complementary RNA sequence without activating cleavage of the target (94) . In test tube experiments, CAG25 was able to invade (CUG)n hairpins, form stable heteroduplexes, liberate MNBL1 protein and prevent it from binding. Treatment of skeletal muscle in HSA LR mice resulted in reduction of nuclear foci, redistribution of Mbnl1 protein and near-normalization of aberrant splicing. Whether CAG25's steric blocking capacity had any direct splice switching effects on other splicing targets is not known. CAG25 treatment restored ClC-1 protein expression and minimized skeletal muscle myotonia (84) .
Contrary to expectation, CAG25 administration resulted also in a 50% reduction of expanded (CUG)n RNA, while endogenous transcripts bearing a short (CUG)n repeat remained unharmed. CAG25 relocated expanded (CUG)n transcripts to the cytoplasm and Wheeler et al. propose that elevated cytoplasmic decay may be responsible for (CUG)n RNA reduction. To what extent the reduction of expanded (CUG)n RNA contributed to the therapeutic effect of CAG25 treatment of HSA LR mice remains to be investigated (32, 84) . Whether CAG25 treatment will have any effect on CUGBP1 expression could not yet be investigated, since CUGBP1 level is normal in HSA LR mice (32) .
Small molecules that bind structured nucleic acids
Important progress was also made in identifying small molecules that liberate MBNL1 by binding to (C/CUG)n repeats (95) (96) (97) . These studies were based on molecules known to bind structured nucleic acids. The most comprehensive analysis was published by Berglund et al. who identified that pentamidine, a drug to treat Pneumocystis carinii infections in AIDS patients, can disrupt MBNL1-(CUG)n hairpin complexes in test tube experiments (95) . Although still speculative, pentamidine is thought to bind the minor groove of A-form (CUG)n repeats and not to disrupt the stem-loop structure (70, 95) . In view of the findings discussed above (78, 84) , one wonders whether expanded (CUG)n RNA levels will change upon pentamidine treatment, but this was not investigated. Pentamidine reduced MBNL1-(CUG)n aggregates in the nucleus and rescued missplicing in a HeLa cell model expressing (CUG)960 RNA and minigene splicing reporters (29) . Intraperitoneal injections in HSA LR mice resulted in mild reversal of missplicing of pre-mRNAs in skeletal muscle. The use of pentamidine is strongly limited by its high toxicity (95) . Future work should therefore concentrate on strategic chemical modification to increase the affinity and specificity and minimize the off-target effects.
Multivalent modular compounds that bind internal RNA loops
Disney et al. (98) (99) (100) (101) constructed multivalent, modularly assembled, flexible (non-nucleic acid type) ligands for highaffinity binding to (C/CUG)n repeats, based on compounds that bind discrete RNA loops. Ligands were screened for their ability to inhibit (C/CUG)n -MBNL1 binding in vitro. The highest affinity binder to a (CCUG)n repeat consisted of three kanamycin A modules on a peptoid backbone (98) . By reducing the distance between the kanamycin modules and increasing the number of modules to four, an equally strong ligand for (CUG)n repeats was created (99) . This study elegantly illustrates that size differences in the internal loops of the two repeat types have to be taken into account in the development of drugs. Furthermore, flexibility in the assembly scaffold was shown to be important for potency (101) . In a separate study by the same group, a pentameric (CUG)n repeat ligand (which also binds (CAG)n repeats) was designed based on Hoechst 33258 modules (100) . A great advantage of these multivalent compounds is that they show high binding affinity-generally with K d 's in the nanomolar range-and are generally cell permeable (98) (99) (100) (101) . Whether these ligands will be able to enter the nucleus and subsequently help expanded transcripts to move to the cytoplasm requires further investigation.
Transcript relocation
Blocking of protein binding to the repeat segment in RNA will almost certainly also affect its fate in intracellular transport. The idea that treatment which promotes export to the cytoplasm may be beneficial to DM cells was first worked out in a study on inclusion of a woodchuck post-transcriptional regulatory element (WPRE) in an artificial transcript bearing an expanded (CUG)200 repeat (102, 103) . The presence of the WPRE promoted nuclear release of the RNA and improved differentiation of myoblasts in which it was expressed. The fact that induction of a shift in nuclear-cytosolic distribution of mutant DMPK RNA may protect against toxicity was confirmed in a mouse model, which expresses Mbnl1-(CUG)400 RNA foci exclusively in the cytoplasm without displaying DM1-typical features (104) . Thus far, no drugs with the specific aim of changing or improving protein binding necessary for nuclear export of expanded (CUG)n transcripts have been described, but their application may have an additional advantage in that cytoplasmic relocation of the mutant transcripts could normalize DMPK protein levels. It still needs to be investigated whether activities of CAG25 (84), PS58 (78) or pentamidine (95) also cause relocation of expanded (CUG)n transcripts to the cytoplasm in cell and animal models. As the (CCUG)n repeat is located in an intron, promotion of nuclear export for therapeutic design may only be appropriate for DM1 and not for DM2.
CONCLUSION AND FUTURE OUTLOOK
About 80 years after the first description of DM and almost 20 years after the discovery of the first DM mutation, a series of promising strategies for selective elimination or
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Human Molecular Genetics, 2010, Vol. 19, Review Issue 1 neutralization of expanded (C/CUG)n transcripts is now emerging. Effective AONs and small molecules are in the pipeline of development, but much work still needs to be done. The biggest hurdle to overcome is efficient delivery of active compounds in vivo (105) (106) (107) . A second important challenge in treating DM is that this multisystemic disease is highly variable which makes it difficult to define target tissues and to develop reliable biomarkers for clinical trials. Also the development of additional, more sophisticated animal models is needed to more accurately model the multisystemic features of these disorders. In summary, although much progress has been made, additional basic and translational studies will be required to better understand the molecular pathogenesis of DM and to develop safe and effective treatment strategies.
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